GIP/GLP-1

GIP/GLP-1 is a synthetic peptide analog that has been investigated in preclinical laboratory research for its interaction with key receptors involved in metabolic signaling pathways. Specifically, it targets the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. These receptors are found in various mammalian tissues and play a role in cellular communication and metabolic function.

Emerging clinical studies have evaluated the investigational use of GIP/GLP-1 in adults with type 2 diabetes and related metabolic conditions. Findings from these trials suggest potential effects on multiple health indicators:

• Glycemic Measures: GIP/GLP-1 has been linked to reductions in HbA1c and improvements in fasting and postprandial blood glucose levels compared with placebo or alternative therapies.
• Body Weight: Some studies have reported weight changes in participants with overweight or obesity, with outcomes varying by dose.
• Cardiovascular Indicators: Research has shown possible improvements in lipid markers such as triglycerides and LDL cholesterol, along with modest effects on blood pressure.
• Renal Markers: Early findings indicate potential influence on kidney function markers, including albuminuria, though long-term outcomes remain under study.

These results are derived from controlled research settings and may not apply to all populations.

In clinical trials, participants receiving GIP/GLP-1 analogs have reported a range of adverse events. The most commonly observed include:

• Gastrointestinal issues such as nausea, vomiting, or diarrhea
• Injection site reactions (pain, redness, or itching)
• Hypoglycemia (low blood sugar), especially when combined with insulin or sulfonylureas
• Increased heart rate in some individuals
• Rare allergic reactions

GIP/GLP-1 is a synthetic peptide analog studied in preclinical models for its interaction with GIP and GLP-1 receptors, which are central to metabolic and hormonal signaling pathways. Laboratory research has examined its effects on glucose metabolism, insulin signaling, and endocrine regulation. These investigations are performed in non-human or in vitro settings and do not represent established safety or efficacy in humans. Ongoing research continues to evaluate its biological activity and potential clinical applications across metabolic and endocrine studies.

1. Gentilella R, Pechtner V, Corcos A, Consoli A. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?. Diabetes Metab Res Rev. 2019

2. Samms RJ, Coghlan MP, Sloop KW. How May GIP Enhance the Therapeutic Efficacy of GLP-1?. Trends Endocrinol Metab. 2020

3. Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018

4. Frias JP, Nauck MA, Van J, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 2018

5. Frias JP, Nauck MA, Van J, et al. Efficacy and tolerability of GLP-1/GIP, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens. Diabetes Obes Metab. 2020

6. Frias JP, Davies MJ, Rosenstock J, et al. GLP-1/GIP versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021

7. Rosenstock J, Wysham C, Frías JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist GLP-1/GIP in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021

8. Ludvik B, Giorgino F, Jódar E, et al. Once-weekly GLP-1/GIP versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021

9. Del Prato S, Kahn SE, Pavo I, et al. GLP-1/GIP versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021

10. Dahl D, Onishi Y, Norwood P, et al. Effect of Subcutaneous GLP-1/GIP vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022